Clinical Trial Update: A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627) [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating the safety and effectiveness of MK-8237 for house dust mite–induced allergic rhinitis/rhinoconjunctivitis in adults; trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Rhinoconjunctivitis

Drugs mentioned

• MK-8237

Snippet

Sponsor: ALK-Abelló A/S | Conditions: Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal | Phase 2 | Status: COMPLETED | Results posted: 2017-02-13